

Long COVID In Adults at 12 Months After Mild-to-Moderate SARS-CoV-2 Infection

Paolo Boscolo-Rizzo¹, Francesco Guida¹, Jerry Polese², Alberto Vito Marcuzzo¹, Vincenzo Capriotti³, Andrea D'Alessandro¹, Enrico Zanelli¹, Riccardo Marzolino¹, Chiara Lazzarin¹, Paolo Antonucci¹, Erica Sacchet¹, Margherita Tofanelli¹, Daniele Borsetto⁴, Nicoletta Gardenal¹, Martino Pengo⁵, and Giancarlo Tirelli¹

¹Department of Medical, Surgical and Health Sciences, Section of Otolaryngology, University of Trieste, Trieste, Italy

²Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy

³Department of Neurosciences, Section of Otolaryngology, Papa Giovanni XXIII General Hospital, Bergamo, Italy

⁴Department of ENT, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

⁵Department of Cardiovascular, Neural and Metabolic Sciences, Istituto Auxologico Italiano IRCCS, Ospedale San Luca, Milano, Italy

Abstract

Background. In a proportion of patients recovered from the acute COVID-19 phase, a variable range of symptoms has been observed to persist for at least 6-months.

Objectives. The main aim of this study was to evaluate the prevalence of COVID-related symptoms 12-months after the onset of mild-to-moderate disease.

Methods Prospective study based on structured questionnaires and additional outcomes.

Results 304/354 patients completing the survey at baseline also completed the follow-up interview (85.9%; median [range] age, 47 [18-76] years; 185 [60.9%] women). Persistence of at least one symptom at 12-months follow-up was reported by 161 patients (53.0%). The most commonly reported symptom of long COVID was felt tired (n=83, 27.3%), followed by smell or taste impairment (n=67, 22.0%), shortness of breath (n=39, 12.8%) and muscle pain (n=28, 9.2%). Being females (OR=1.64; 95% CI: 1.00-2.70), aged between 40-54 (OR=1.92; 95% CI: 1.07-3.44), having a BMI \geq 25 (OR=1.67; 95% CI: 1.00-2.78), and experiencing more symptoms during the acute phase of the disease (OR=8.71 for \geq 8

symptoms; 95% CI: 2.73-27.76) were associated with long COVID. Persistence of symptoms showed a significant impact on quality of life ($p < 0.0001$) and depression scale scores ($p = 0.0102$).

Conclusion More than half of patients with previous mild-to-moderate symptomatic COVID-19 complained the persistence of at least one symptom 12-months after the onset of the illness.

Key words: COVID-19; chronic COVID syndrome; long COVID; long haulers; SARS-CoV-2

Funding: None

Conflict of interest: The authors declare that they have no conflicts of interest

Availability of data and material: The authors confirm that the data supporting the findings of this study are available within the article

Code availability: not applicable

Author Contributions: Drs Boscolo-Rizzo and Guida had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis

Concept and design: Drs Boscolo-Rizzo, Guida, Pengo and Tirelli

Acquisition, analysis, or interpretation of data: Drs Boscolo-Rizzo, Guida, Polesel, Marcuzzo, Antonucci, Capriotti, Sacchet, D'Alessandro, Zanelli, Marzolino, Lazzarin, Tofaneli, Gardenal, Borsetto

Drafting of the manuscript: Drs Boscolo-Rizzo, Guida, Polesel, Pengo, Tirelli

Critical revision of the manuscript for important intellectual content: Drs Boscolo-Rizzo, Guida, Polesel, Borsetto, Pengo, Tirelli

Statistical analysis: Polesel

Supervision: Drs Boscolo-Rizzo and Tirelli

Ethics approval: The study was approved by the Ethics Committee of the Friuli Venezia Giulia Region (CEUR-2020-Os-156)

Informed consent: Additional informed consent was obtained from all individual participants for whom identifying information is included in this article

Introduction

Since the first cases in China in December 2019, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally causing a pandemic [1]. SARS-CoV-2 infection can cause a wide array of symptoms ranging from mild to severe or fatal forms with a substantial fraction of cases remaining asymptomatic carriers [2]. In symptomatic subjects, the most prevalent symptoms are cough, fever, fatigue, smell or taste impairment, myalgias, and gastrointestinal symptoms [3].

Furthermore, it has been observed that in a proportion of patients recovered from the acute phase, a variable range of symptoms may persist for a long time [4,5] and the persistence of symptoms has a significant impact on health-related quality of life (QoL) [6].

There is still no consensus on how to call this condition: the names "chronic COVID", "chronic COVID syndrome", "long haulers", "long COVID" have been used with the latter being the most widespread among patients and in the literature [7,8]. Also, there is a lack of a clear definition and criteria to identify this condition. Mahase defined it as: "illness in people who have either recovered from COVID-19 but are still report lasting effects of the infection or have had the usual symptoms for far longer than would be expected" [9]. A similar condition has developed during the other coronaviruses' outbreaks, i.e., severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) [10].

An increasing number of studies have been focused on long COVID, but they have mainly been concentrated on previously hospitalized severe COVID-19 patients reporting symptoms up to 6-months after illness [5,11–14]. The main aim of this study was to evaluate the prevalence of COVID-related symptoms 12-months after the onset of mild-to-moderate disease.

Materials and Methods

Subjects

We conducted a prospective study on mild-to-moderate symptomatic adult patients consecutively assessed at Cattinara University Hospital, Trieste, Italy between March 1 and March 31, 2020, who tested positive for SARS-CoV-2 RNA by polymerase chain reaction (PCR) on nasopharyngeal and throat swabs performed according to World Health Organization recommendation [15]. All patients were initially home-isolated with mild-to-moderate symptoms. Patients were considered mildly symptomatic if they had less severe clinical symptoms with no evidence of pneumonia, not requiring hospitalization, and therefore considered suitable for being treated at home. As this study was within a research project aimed to assess the prevalence of chemosensory dysfunction in patients with SARS-CoV-2 infection[16], patients with a history of previous trauma, surgery or radiotherapy in the oral and nasal cavities, allergic rhinitis or rhinosinusitis, previous olfactory or gustative dysfunction, or psychiatric or neurological diseases, were excluded from the study.

354 (71.4%) of the 496 eligible patients completed the baseline telephone interview administered within 3 weeks after the first positive swab performed between 1st – 31st March 2020. The median time from symptoms onset to SARS-CoV-2 testing was 7 days (interquartile range, 4-12 days). All patients completing the baseline interview were phoned from 5th to 22nd March 2021, so that all patients were recontacted 12-months after the onset of symptoms; in case of a non-response, patients were re-contacted twice.

Questionnaires

All patients were asked the same questions. Baseline demographic and clinical data, obtained at the time of acute illness or retrospectively within 30-day from the first positive swab, were collected through *ad hoc* questions administered by telephone interview and included gender, age, self-reported height and weight, smoking and alcohol habits, and the following co-morbidities: immunosuppression, diabetes, cardiovascular diseases, active cancer, chronic respiratory disease, kidney disease, liver disease. Obesity was defined as having a body mass index (BMI) ≥ 30 . Symptoms were assessed through *ad hoc* questions and structured questionnaire, i.e., the Acute Respiratory Tract Infection Questionnaire (ARTIQ). In addition, during the follow-up interview patients were asked about their general health perception and the presence of depression. Briefly, a single item was used to assess general health

perceptions. Patients were asked to rate their overall health on a scale of 0-10, with 0 representing 'worst health' and 10 representing perfect health according to Cleary et al. [17]. Patients were also asked “on a scale of 0–10, with zero being no depression and 10 being the worst depression you can imagine, how would you rate the worst depression you have now?”[18].

Statistical analysis

Symptom prevalence was expressed as percentage of total patients, and 95% confidence interval (CI) were calculated using Clopper-Pearson method; differences in prevalence were evaluated through Fisher’s exact test. Odds ratio (OR) of symptoms’ persistence and corresponding 95% confidence intervals (CI) were calculated through unconditional logistic regression model, adjusting for sex, age and number of symptoms during the acute Covid-19 phase. To account for potential bias of sex and age, differences in mean value of quality of life and depression were tested through the analysis of variance (ANOVA). Analyses were performed using R 3.6. and statistical significance was claimed for $p < 0.05$ (two-tailed).

Results

Of 354 patients completing the survey at baseline, 304 also completed the 12-months follow-up survey (85.9%). Baseline socio-demographic and clinical characteristics of 304 patients are reported in Table 1. The median age of the study cohort was 47 years (range 18-76 years). There was a female preponderance with 185 out of 304 being females (60.9%). Associated co-morbidities were reported by 98 cases (32.3%) with the most common being obesity (n=36, 11.8%) followed by cardiovascular disease (n=26, 8.6%) and chronic respiratory disease (n=21, 6.9%).

The median time to achieving a negative swab was 23 days (interquartile range, 15-32 days). Figure 1 and Supplementary Table 1 report the prevalence of symptoms in the acute phase of COVID-19 and at 12-months follow-up. During the acute phase of COVID-19 the most frequently reported symptoms were fever (n=232, 76.3%), felt tired (n=216, 71.1%), smell impairment (n=201, 66.1%), taste impairment (n=198, 65.1%) and joint pain (n=181, 59.5%).

Persistence of at least one symptom at 12-months follow-up was reported by 161 patients (53.0%). The symptom that most frequently persisted at 12-months was felt tired (n=83, 27.3%), followed by smell or taste impairment (n=67, 22.0%) with smell being altered in 62 patients (20.4%) and taste in 46 (15.1%), shortness of breath (n=39, 12.8%) and muscle pain (n=28, 9.2%).

The risk of symptom's persistence at 12-months follow-up was trendily higher in females (OR=1.64; 95% CI: 1.00-2.70; p=0.0505), and significantly higher in subjects aging between 40-54 (OR=1.92; 95% CI: 1.07-3.44; p=0.0290) and in those with a BMI ≥ 25 (OR=1.67; 95% CI: 1.00-2.78; p=0.0492). The presence of 3 to 7 symptoms during the acute phase of the disease resulted associated with a significant higher odd of symptom's persistence after 12-months (OR=3.22; 95% CI: 1.01-10.24; p=0.0475). This association resulted stronger in those having ≥ 8 symptoms (OR=8.71; 95% CI: 2.73-27.76; p=0.0003) (Table 2).

In long haulers, 8 patients (5.0%; 95% CI: 2.2-9.6%) had QoL scores ≤ 5 and 23 patients (14.3%; 95% CI: 9.3-20.7%) had a depression score ≥ 5 . Persistence of symptoms 12-months after the onset was associated with worse quality of life (p<0.0001) and worse scores on depression scale (p=0.0102). In particular, quality of life was significantly affected by

felt tired ($p < 0.0001$), shortness of breath ($p = 0.0015$) and insomnia ($p = 0.0379$), while felt tired significantly impact on scores on depression scale ($p = 0.0082$) (Table 3).

Discussion

To our knowledge, this is the cohort study with longest follow-up duration assessing the prevalence of persistent symptoms in COVID-19 patients. We observed that 12-months after the onset of illness, 53.0% of patients with mild-to-moderate COVID-19 endorsed at least one persistent symptom. A previous investigation in a large cohort of patients with COVID-19 discharged from hospital reported a at least one symptom in 76% of cases 6-months after acute infection [12], while in another study, including outpatients with mild disease, approximately 30% reported persistent symptoms at 6-months [14]. Thus, taking into account that our series included only outpatients with mild-to-moderate COVID-19 representing the overwhelming majority of COVID-19 patients [3], the rate of long COVID observed in the present cohort is quite worrying. Although few patients had QoL scores ≤ 5 and depression score ≥ 5 , the persistence of symptoms 12-months after the onset was associated with worse quality of life and worse scores on depression scale. Recent investigations have observed a significant impairment in QoL in patients previously hospitalized for COVID-19 [6] and a worsening of QoL was described in about one third of patients 6-months after the acute illness [14]. Considering the continued worldwide spread of SARS-CoV-2 infection, the burden of long haulers on the health care systems will be pressing and urged researchers to identify subjects at risk of long COVID for trials of strategies for prevention or treatment and to plan education and rehabilitation services in order to face with the considerable health and economic concerns [4].

In agreement with other evidence, the most commonly reported symptom was fatigue followed by chemosensory dysfunction [4,5,14]. Fatigue was reported by 27% of patients. Previous investigations with long-term follow-up have observed a frequency of this symptom of 14% [14] to 63% [12] at 6-months with higher prevalence recorded in a series including only hospitalized subjects. An altered sense of smell or taste was the second more common symptom of long COVID in the present series reported by 22.0% of subjects. Chemosensory dysfunction has been consistently reported as one of the most predominant symptom during the acute phase of the disease as well as among the most frequent long-lasting symptoms in patients with COVID-19 [19,20] with a higher prevalence in patients with mild-to-moderate disease [21]. Consistently, series including outpatients [4,14] have observed a higher rate of long-term chemosensory impairment compared to those including only patients with severe COVID-19 [12], while one study not using structured questionnaires failed to provide data about the prevalence of altered sense of smell or taste in the context of long COVID syndrome [11]. Furthermore, anosmia was recently reported as one of the symptoms characterizing the long COVID syndrome among a large series of app users [4]. Some authors have speculated that

mild-to-moderate COVID-19 patients may be affected by nasal-centric viral spread, whereas patients requiring hospitalization may be experiencing a more pulmonary-centric and systemic viral infection thus impacting the prevalence of different symptoms both in acute phase and in the context of long COVID syndrome [22]. However, although all patients in the study had mild to moderate disease without evidence of pneumonia, 13% still reported shortness of breath at 12-months follow-up interview. Interestingly, an abnormal pulmonary function consisting in an impaired diffusing-capacity was observed in 30% of patients after the acute phase of mild COVID-19 without pneumonia [23].

In addition to the different settings and timing of symptoms detection, an important source of heterogeneity in reporting the prevalence of symptoms in patients with long COVID is the lack of using a validated questionnaire. To date, no standardized tool has been proposed yet for a uniform and comprehensive evaluation and reporting of symptoms in COVID-19 patients. In the present study *ad hoc* questions were used as well as a structured questionnaire, the ARTIQ, as it was demonstrated to be a validated tool to assess the severity and functional impacts of acute respiratory tract infections [24].

Experiencing more symptoms at baseline was the most significant factor associated with long COVID. This is in line with recent evidence showing that subjects complaining more than 5 symptoms during the first week of illness are more prone to develop long COVID [4]. Moreover, the prevalence of long haulers was higher in females, patients in their middle age and those with BMI ≥ 25 . Thus, models to identify patients at risk for long COVID may be developed.

This study has several limitations. First, the absence of a control group may impact on the interpretation of results. The single-centre study design and the relatively small number of sample size may restrict its generalizability. Hospitalized patients were not included in the study. Although this made our cohort more homogeneous, studies comparing the long-term outcomes in inpatients and outpatients are definitely needed. Symptoms were self-reported and based on telephone interview. Though, we tried to perform a comprehensive symptoms assessment by using *ad hoc* questions and a structured questionnaire, some symptoms may have been undetected. The QoL and depression assessment was performed only at 12-months follow-up. Thus, we were unable to report a worsenig in the QoL and depression scale scores.

In conclusion, our study indicates that persistent symptoms of SARS-CoV-2 infection can be detected beyond 12-months from the onset of the illness in more than half of patients with mild-to-moderate disease. Identifying patients at risk for prevention and treatment will be critical to improving outcomes and reducing health costs. Finally, a structured and validated questionnaire for the assessment of symptoms in COVID-19 patients is highly desirable to characterize the full clinical spectrum of long COVID and improve the reliability and reproducibility of clinical studies.

References

- [1] Z. Wu, J.M. McGoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, *JAMA*. (2020). <https://doi.org/10.1001/jama.2020.2648>.
- [2] W.J. Wiersinga, A. Rhodes, A.C. Cheng, S.J. Peacock, H.C. Prescott, Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review, *JAMA*. 324 (2020) 782–793. <https://doi.org/10.1001/jama.2020.12839>.
- [3] R.T. Gandhi, J.B. Lynch, C. del Rio, Mild or Moderate Covid-19, *N. Engl. J. Med.* 383 (2020) 1757–1766. <https://doi.org/10.1056/NEJMcpc2009249>.
- [4] C.H. Sudre, B. Murray, T. Varsavsky, M.S. Graham, R.S. Penfold, R.C. Bowyer, J.C. Pujol, K. Klaser, M. Antonelli, L.S. Canas, E. Molteni, M. Modat, M. Jorge Cardoso, A. May, S. Ganesh, R. Davies, L.H. Nguyen, D.A. Drew, C.M. Astley, A.D. Joshi, J. Merino, N. Tsereteli, T. Fall, M.F. Gomez, E.L. Duncan, C. Menni, F.M.K. Williams, P.W. Franks, A.T. Chan, J. Wolf, S. Ourselin, T. Spector, C.J. Steves, Attributes and predictors of long COVID, *Nat. Med.* (2021). <https://doi.org/10.1038/s41591-021-01292-y>.
- [5] A. Carfi, R. Bernabei, F. Landi, Gemelli Against COVID-19 Post-Acute Care Study Group, Persistent Symptoms in Patients After Acute COVID-19, *JAMA*. 324 (2020) 603–605. <https://doi.org/10.1001/jama.2020.12603>.
- [6] S. van der Sar-van der Brugge, S. Talman, L. Boonman-de Winter, M. de Mol, E. Hoefman, R.W. van Etten, I.C. De Backer, Pulmonary function and health-related quality of life after COVID-19 pneumonia, *Respir. Med.* 176 (2021) 106272. <https://doi.org/10.1016/j.rmed.2020.106272>.
- [7] A.M. Baig, Chronic COVID syndrome: Need for an appropriate medical terminology for long-COVID and COVID long-haulers, *J. Med. Virol.* (2020). <https://doi.org/10.1002/jmv.26624>.
- [8] Long COVID: let patients help define long-lasting COVID symptoms, *Nature*. 586 (2020) 170. <https://doi.org/10.1038/d41586-020-02796-2>.
- [9] E. Mahase, Covid-19: What do we know about “long covid”?, *BMJ*. 370 (2020) m2815. <https://doi.org/10.1136/bmj.m2815>.
- [10] O. O’Sullivan, Long-term sequelae following previous coronavirus epidemics, *Clin. Med.* 21 (2021) e68–e70. <https://doi.org/10.7861/clinmed.2020-0204>.
- [11] Q. Xiong, M. Xu, J. Li, Y. Liu, J. Zhang, Y. Xu, W. Dong, Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study, *Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.* 27 (2021) 89–95. <https://doi.org/10.1016/j.cmi.2020.09.023>.
- [12] C. Huang, L. Huang, Y. Wang, X. Li, L. Ren, X. Gu, L. Kang, L. Guo, M. Liu, X. Zhou, J. Luo, Z. Huang, S. Tu, Y. Zhao, L. Chen, D. Xu, Y. Li, C. Li, L. Peng, Y. Li, W. Xie, D. Cui, L. Shang, G. Fan, J. Xu, G. Wang, Y. Wang, J. Zhong, C. Wang, J. Wang, D. Zhang, B. Cao, 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study, *The Lancet*. 397 (2021). [https://doi.org/10.1016/S0140-6736\(20\)32656-8](https://doi.org/10.1016/S0140-6736(20)32656-8).
- [13] H. Klein, K. Asseo, N. Karni, Y. Benjamini, R. Nir-Paz, M. Muszkat, S. Israel, M.Y. Niv, Onset, duration, and persistence of taste and smell changes and other COVID-19 symptoms: longitudinal study in Israeli patients, *MedRxiv*. (2020) 2020.09.25.20201343. <https://doi.org/10.1101/2020.09.25.20201343>.
- [14] J.K. Logue, N.M. Franko, D.J. McCulloch, D. McDonald, A. Magedson, C.R. Wolf, H.Y. Chu, Sequelae in Adults at 6 Months After COVID-19 Infection, *JAMA Netw. Open*. 4 (2021) e210830. <https://doi.org/10.1001/jamanetworkopen.2021.0830>.
- [15] Technical guidance, (n.d.). <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance> (accessed March 25, 2020).
- [16] P. Boscolo-Rizzo, F. Guida, J. Polesel, A.V. Marcuzzo, P. Antonucci, V. Capriotti, E. Sacchet, F. Cragolini, A. D’Alessandro, E. Zanelli, R. Marzolino, C. Lazzarin, M. Tofanelli, N. Gardenal, D. Borsetto, C. Hopkins, L.A. Vaira, G. Tirelli, Self-reported smell and taste recovery in COVID-19 patients: a one-year prospective study, *MedRxiv*. (2021) 2021.03.18.21253862. <https://doi.org/10.1101/2021.03.18.21253862>.
- [17] P.D. Cleary, G. Morrissey, G. Oster, Health-related quality of life in patients with advanced prostate cancer: a multinational perspective, *Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil.* 4 (1995) 207–220. <https://doi.org/10.1007/BF02260860>.
- [18] S.Z. Pantilat, D.L. O’Riordan, S.L. Dibble, C.S. Landefeld, An assessment of the screening performance of a single-item measure of depression from the Edmonton Symptom Assessment Scale among chronically ill hospitalized patients, *J. Pain Symptom Manage.* 43 (2012) 866–873. <https://doi.org/10.1016/j.jpainsymman.2011.05.022>.
- [19] G. Spinato, C. Fabbris, J. Polesel, D. Cazzador, D. Borsetto, C. Hopkins, P. Boscolo-Rizzo, Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection, *JAMA*. 323 (2020) 2089–2090. <https://doi.org/10.1001/jama.2020.6771>.

- [20] P. Boscolo-Rizzo, J. Polese, G. Spinato, A. Menegaldo, C. Fabbris, L. Calvanese, D. Borsetto, C. Hopkins, Predominance of an altered sense of smell or taste among long-lasting symptoms in patients with mildly symptomatic COVID-19, *Rhinology*. 58 (2020) 524–525. <https://doi.org/10.4193/Rhin20.263>.
- [21] D. Borsetto, C. Hopkins, V. Philips, R. Obholzer, G. Tirelli, J. Polese, P. Boscolo-Rizzo, Self-reported alteration of sense of smell or taste in patients with COVID-19: a systematic review and meta-analysis on 3563 patients, *Rhinology*. 58 (2020) 430–436. <https://doi.org/10.4193/Rhin20.185>.
- [22] C.H. Yan, F. Faraji, D.P. Prajapati, C.E. Boone, A.S. DeConde, Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms, *Int. Forum Allergy Rhinol.* (2020). <https://doi.org/10.1002/alr.22579>.
- [23] X. Mo, W. Jian, Z. Su, M. Chen, H. Peng, P. Peng, C. Lei, S. Li, R. Chen, N. Zhong, Abnormal pulmonary function in COVID-19 patients at time of hospital discharge, *Eur. Respir. J.* (2020). <https://doi.org/10.1183/13993003.01217-2020>.
- [24] R. Aabenhus, H. Thorsen, V. Siersma, J. Brodersen, The development and validation of a multidimensional sum-scaling questionnaire to measure patient-reported outcomes in acute respiratory tract infections in primary care: the acute respiratory tract infection questionnaire, *Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res.* 16 (2013) 987–992. <https://doi.org/10.1016/j.jval.2013.06.011>.




Figure 1. COVID-19-Related Symptoms

The figure reports the percentages of patients with COVID-19-related symptoms during the acute phase of illness (blue) and at 12-months follow-up (orange) according to severity (light=mild; dark=severe)

ARTIQ: *Acute* *Respiratory* *Tract* *Infection* *Questionnaire*

Table 1. Sociodemographic and clinical characteristics of 304 patients positive for COVID-19

	n	(%)
Gender		
Male	119	(39.1)
Female	185	(60.9)
Age (years) ^a		
<40	93	(30.6)
40-54	119	(39.1)
≥55	92	(30.3)
Smoking habits		
Never	179	(58.9)
Former	74	(24.3)
Current	51	(16.8)
Drinking habits		
Never	202	(66.5)
Former	30	(9.9)
Current	72	(23.7)
BMI (kg m ⁻²)		
<25	170	(55.9)
≥25	134	(44.1)
Comorbidity		
None	206	(67.8)
Any	98	(32.2)
Obesity	36	(11.8)
Cardiovascular disease	26	(8.6)
Chronic respiratory disease	21	(6.9)
Immunosuppression	18	(5.9)
Diabetes	10	(3.3)
Cancer	5	(1.6)
Liver disease	5	(1.6)
Kidney disease	2	(0.7)
Time for a negative swab (days)		
≤23	157	(51.6)
>23	147	(48.4)

BMI: *body mass index*

^aMedian age (IQR): 47 years (37-56)

Table 2. Odds ratio and corresponding 95% confidence interval for symptoms persistence at 12-months follow-up according to sociodemographic and clinical characteristics in 304 patients positive for COVID-19

	Symptoms persistence				OR (95% CI) ^a	Wald χ^2
	Yes		No			
	n	(%)	n	(%)		
Gender						
Male	41	(42.9)	68	(57.1)	Reference	
Female	110	(59.5)	75	(40.5)	1.64 (1.00-2.70)	p=0.0505
Age (years)						
<40	39	(41.9)	54	(58.1)	Reference	
40-54	73	(61.3)	46	(38.7)	1.92 (1.07-3.44)	p=0.0290
≥55	49	(53.3)	43	(46.7)	1.56 (0.84-2.90)	p=0.1555
Smoking habits						
Never	96	(53.6)	83	(46.4)	Reference	
Ever	65	(52.0)	60	(48.0)	0.93 (0.57-1.53)	p=0.7847
Drinking habits						
Never	114	(56.4)	88	(43.6)	Reference	
Ever	47	(46.1)	55	(53.9)	0.67 (0.39-1.14)	p=0.1400
BMI (kg m ⁻²)						
<25	79	(46.5)	91	(53.5)	Reference	
≥25	82	(61.2)	52	(38.8)	1.67 (1.00-2.78)	p=0.0492
Comorbidity						
None	100	(48.5)	106	(51.5)	Reference	
Any	61	(61.2)	37	(37.8)	1.42 (0.83-2.43)	p=0.2061
Time for a negative swab (days)						
≤23	80	(51.0)	77	(49.0)	Reference	
>23	81	(55.1)	66	(44.9)	1.27 (0.78-2.06)	p=0.3415
Number of symptoms during acute phase of COVID-19						
≤2	4	(19.1)	17	(89.9)	Reference	
3-7	58	(42.0)	80	(58.0)	3.22 (1.01-10.24)	p=0.0475
8+	99	(68.3)	46	(31.7)	8.71 (2.73-27.76)	p=0.0003

BMI: *body mass index*

^aEstimated from unconditional logistic regression model, adjusting for gender, age and number of symptoms during the acute COVID-19 phase.

Table 3. Mean value and standard deviation (std) of quality of life (0=the worst; 10=the best) and depression (0=the best; 10=the worst) at 12-months follow-up in 304 patients COVID-19

	Quality of life		Depression	
	Mean (std)	ANOVA ^a	Mean (std)	ANOVA ^a
Gender				
Male	8.39 (1.12)	p=0.0787	1.98 (1.63)	p=0.0339
Female	8.04 (1.61)		2.52 (2.17)	
Age (years)				
<40	8.65 (1.18)	p=0.0030	2.10 (1.68)	p=0.4489
40-54	8.01 (1.55)		2.54 (2.06)	
≥55	7.92 (1.46)		2.24 (2.17)	
Comorbidities				
None	8.29 (1.58)	p=0.2125	2.27 (2.01)	p=0.3487
Any	7.95 (1.09)		2.49 (1.93)	
Persistent symptoms				
None	8.65 (1.30)	p<0.0001	1.94 (1.85)	p=0.0102
Any	7.75 (1.44)		2.64 (2.06)	
Persistent shortness of breath				
No	8.30 (1.44)	p=0.0015	2.25 (1.95)	p=0.3525
Yes	7.36 (1.20)		2.72 (2.24)	
Persistent felt tired				
No	8.45 (1.28)	p<0.0001	2.10 (1.79)	p=0.0082
Yes	7.46 (1.62)		2.87 (2.37)	
Persistent insomnia				
No	8.23 (1.46)	p=0.0379	2.26 (1.98)	p=0.1429
Yes	7.50 (1.10)		3.00 (2.07)	
Persistent impairment of sense of smell or taste				
No	8.26 (1.46)	p=0.0532	2.22 (2.05)	p=0.2084
Yes	7.88 (1.39)		2.63 (1.75)	

^aAnalysis of Variance (ANOVA) was performed through generalized linear model for unbalanced data adjusted from gender and age

Supplementary Table 1. Evolution of COVID-19-related symptoms in 304 patients

Symptoms	Post-COVID-19 12-months follow-up		Acute COVID-19 phase	
	n	% (95% CI)	n	% (95% CI)
Any symptom	161	53.0 (47.2-58.7)	304	100 (98.8-100)
ARTIQ				
Felt tired	83	27.3 (22.4-32.7)	216	71.1 (65.6-76.1)
Shortness of breath	39	12.8 (9.3-17.1)	95	31.3 (26.1-36.8)
Muscle pain	28	9.2 (6.2-13.0)	175	57.6 (51.8-63.2)
Joint pain	27	8.9 (5.9-12.7)	181	59.5 (53.8-65.1)
Problems breathing	17	5.6 (3.3-8.8)	71	23.4 (18.7-28.5)
Dry cough	10	3.2 (1.6-6.0)	131	43.1 (37.5-48.9)
Headache	10	3.2 (1.6-6.0)	144	47.4 (41.6-53.1)
Blocked nose	9	3.0 (1.4-5.5)	62	20.4 (16.0-25.4)
Chest pain	9	3.0 (1.4-5.5)	70	23.0 (18.4-28.2)
Sore throat	6	2.0 (0.7-4.2)	67	22.0 (17.5-27.1)
Sinonasal pain	6	2.0 (0.7-4.2)	28	9.2 (6.2-13.0)
Weezing	5	1.6 (0.5-3.8)	23	7.6 (4.9-11.1)
Coughing up mucus	4	1.3 (0.4-3.3)	24	7.9 (5.1-11.5)
Fever	2	0.7 (0.1-2.4)	232	76.3 (71.1-81.0)
Loss of appetite	1	0.3 (0.0-1.8)	96	31.6 (26.4-37.1)
Other symptoms				
Smell impairment	62	20.4 (16.0-25.4)	201	66.1 (60.5-71.4)
Taste impairment	46	15.1 (11.3-19.7)	198	65.1 (59.5-70.5)
Insomnia	22	7.2 (4.6-10.8)	77	25.3 (20.5-30.6)
Dizziness	10	3.2 (1.6-6.0)	36	11.8 (8.4-16.0)
Diarrhoea	5	1.6 (0.5-3.8)	98	32.2 (27.0-37.8)
Nausea	5	1.6 (0.5-3.8)	56	18.4 (14.2-23.2)
Red eyes	3	1.0 (0.2-2.9)	41	13.5 (9.9-17.8)
Abdominal pain	2	0.7 (0.1-2.4)	40	13.2 (9.6-17.5)
Vomit	0	0.0 (0.0-1.2)	19	6.3 (3.8-9.6)

ARTIQ: *Acute Respiratory Tract Infection Questionnaire*